000128269 001__ 128269
000128269 005__ 20240228135049.0
000128269 0247_ $$2doi$$a10.1182/blood-2014-05-578070
000128269 0247_ $$2pmid$$apmid:25270908
000128269 0247_ $$2ISSN$$a0006-4971
000128269 0247_ $$2ISSN$$a1528-0020
000128269 0247_ $$2altmetric$$aaltmetric:2735123
000128269 037__ $$aDKFZ-2017-04286
000128269 041__ $$aeng
000128269 082__ $$a610
000128269 1001_ $$aSchlenk, Richard F$$b0
000128269 245__ $$aDifferential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.
000128269 260__ $$aStanford, Calif.$$bHighWire Press$$c2014
000128269 3367_ $$2DRIVER$$aarticle
000128269 3367_ $$2DataCite$$aOutput Types/Journal article
000128269 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1523609845_31445
000128269 3367_ $$2BibTeX$$aARTICLE
000128269 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128269 3367_ $$00$$2EndNote$$aJournal Article
000128269 520__ $$aThe objective was to evaluate the prognostic and predictive impact of allelic ratio and insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene mutations, with regard to postremission therapy in 323 patients with FLT3-ITD-positive acute myeloid leukemia (AML). Increasing FLT3-ITD allelic ratio (P = .004) and IS in the tyrosine kinase domain 1 (TKD1, P = .06) were associated with low complete remission (CR) rates. After postremission therapy including intensive chemotherapy (n = 121) or autologous hematopoietic stem cell transplantation (HSCT, n = 17), an allelic ratio ≥ 0.51 was associated with an unfavorable relapse-free (RFS, P = .0008) and overall survival (OS, P = .004); after allogeneic HSCT (n = 93), outcome was significantly improved in patients with a high allelic ratio (RFS, P = .02; OS, P = .03), whereas no benefit was seen in patients with a low allelic ratio (RFS, P = .38; OS, P = .64). Multivariable analyses revealed a high allelic ratio as a predictive factor for the beneficial effect of allogeneic HSCT; ITD IS in TKD1 remained an unfavorable factor, whereas no prognostic impact of concurrent gene mutations was observed. The clinical trials described herein were previously published or are registered as follows: AMLHD93 and AMLHD98A, previously published; AML SG 07-04, ClinicalTrials.gov identifier #NCT00151242.
000128269 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000128269 588__ $$aDataset connected to CrossRef, PubMed,
000128269 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aFLT3 protein, human
000128269 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$afms-Like Tyrosine Kinase 3
000128269 7001_ $$aKayser, Sabine$$b1
000128269 7001_ $$aBullinger, Lars$$b2
000128269 7001_ $$aKobbe, Guido$$b3
000128269 7001_ $$aCasper, Jochen$$b4
000128269 7001_ $$aRinghoffer, Mark$$b5
000128269 7001_ $$aHeld, Gerhard$$b6
000128269 7001_ $$aBrossart, Peter$$b7
000128269 7001_ $$aLübbert, Michael$$b8
000128269 7001_ $$aSalih, Helmut R$$b9
000128269 7001_ $$aKindler, Thomas$$b10
000128269 7001_ $$aHorst, Heinz A$$b11
000128269 7001_ $$aWulf, Gerald$$b12
000128269 7001_ $$aNachbaur, David$$b13
000128269 7001_ $$aGötze, Katharina$$b14
000128269 7001_ $$aLamparter, Alexander$$b15
000128269 7001_ $$aPaschka, Peter$$b16
000128269 7001_ $$aGaidzik, Verena I$$b17
000128269 7001_ $$aTeleanu, Veronica$$b18
000128269 7001_ $$aSpäth, Daniela$$b19
000128269 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b20$$udkfz
000128269 7001_ $$aKrauter, Jürgen$$b21
000128269 7001_ $$aGanser, Arnold$$b22
000128269 7001_ $$aDöhner, Hartmut$$b23
000128269 7001_ $$aDöhner, Konstanze$$b24
000128269 7001_ $$aGroup, German-Austrian AML Study$$b25$$eCollaboration Author
000128269 773__ $$0PERI:(DE-600)1468538-3$$a10.1182/blood-2014-05-578070$$gVol. 124, no. 23, p. 3441 - 3449$$n23$$p3441 - 3449$$tBlood$$v124$$x1528-0020$$y2014
000128269 909CO $$ooai:inrepo02.dkfz.de:128269$$pVDB
000128269 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000128269 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000128269 9141_ $$y2014
000128269 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD : 2015
000128269 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128269 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128269 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128269 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128269 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128269 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128269 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128269 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128269 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128269 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128269 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128269 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128269 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBLOOD : 2015
000128269 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000128269 980__ $$ajournal
000128269 980__ $$aVDB
000128269 980__ $$aI:(DE-He78)C060-20160331
000128269 980__ $$aUNRESTRICTED